ADIPOR1 and nasopharyngeal carcinoma: From a translational perspective, we have tested if stimulation of adiponectin receptor activity would attenuate the growth of human nasopharyngeal carcinoma, and applied AdipoRon, the first oral adiponectin receptor agonist capable of binding and activating both AdipoR1 and AdipoR2 [47], in the human NPC model.